Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Quoc-Dien Trinh, M.D.

Co-Author

This page shows the publications co-authored by Quoc-Dien Trinh and Matthew Mossanen.
Connection Strength

3.820
  1. Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures. Am J Surg. 2021 Apr 14.
    View in: PubMed
    Score: 0.245
  2. Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. Minerva Urol Nephrol. 2021 06; 73(3):404-406.
    View in: PubMed
    Score: 0.245
  3. Temporal trends in the incidence of distant-stage bladder cancer among young individuals. Int J Urol. 2021 06; 28(6):704-705.
    View in: PubMed
    Score: 0.244
  4. The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer. 2021 May 01; 127(9):1387-1394.
    View in: PubMed
    Score: 0.240
  5. Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era? Urology. 2021 Jan; 147:199-204.
    View in: PubMed
    Score: 0.234
  6. Delayed blood transfusion is associated with mortality following radical cystectomy. Scand J Urol. 2020 Aug; 54(4):290-296.
    View in: PubMed
    Score: 0.232
  7. Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2020 12; 18(6):e651-e659.
    View in: PubMed
    Score: 0.228
  8. Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World J Urol. 2020 Sep; 38(9):2227-2236.
    View in: PubMed
    Score: 0.223
  9. The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. Cancer. 2020 02 01; 126(3):496-505.
    View in: PubMed
    Score: 0.221
  10. Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology. 2020 Jan; 135:44-49.
    View in: PubMed
    Score: 0.221
  11. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus. 2021 Jan; 7(1):124-131.
    View in: PubMed
    Score: 0.216
  12. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU Int. 2019 07; 124(1):40-46.
    View in: PubMed
    Score: 0.214
  13. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019 05 01; 125(9):1449-1458.
    View in: PubMed
    Score: 0.210
  14. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019 Oct; 37(10):2059-2065.
    View in: PubMed
    Score: 0.208
  15. Associations of specific postoperative complications with costs after radical cystectomy. BJU Int. 2018 03; 121(3):428-436.
    View in: PubMed
    Score: 0.194
  16. Approach to the Patient with High-Risk Prostate Cancer. Urol Clin North Am. 2017 Nov; 44(4):635-645.
    View in: PubMed
    Score: 0.193
  17. Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. Eur Urol. 2018 Mar; 73(3):374-382.
    View in: PubMed
    Score: 0.190
  18. Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol. 2021 Jul; 39(7):436.e1-436.e10.
    View in: PubMed
    Score: 0.061
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.